Ani Pharmaceuticals (ANIP) Total Current Liabilities (2010 - 2026)

Ani Pharmaceuticals has disclosed Total Current Liabilities across 17 years of filings, most recently posting $239.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $239.5 million, up 18.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $239.5 million (up 18.68% YoY), and the FY2025 annual result was $278.1 million, up 43.02% from the prior year.
• Total Current Liabilities came in at $239.5 million for Q1 2026 at Ani Pharmaceuticals, down from $278.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $278.1 million in Q4 2025 to a low of $79.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $140.0 million (2024), against an average of $163.1 million.
• Across the five-year window, Total Current Liabilities declined 3.91% in 2022 and surged 69.19% in 2025, its largest moves.
• Ani Pharmaceuticals' Total Current Liabilities stood at $99.4 million in 2022, then soared by 46.3% to $145.5 million in 2023, then surged by 33.67% to $194.5 million in 2024, then soared by 43.02% to $278.1 million in 2025, then retreated by 13.88% to $239.5 million in 2026.
• The last three Total Current Liabilities figures came in at $239.5 million (Q1 2026), $278.1 million (Q4 2025), and $270.6 million (Q3 2025), per Business Quant data.